Synthetic lipo-MDP analogs as mucosal adjuvants for animal vaccines

合成脂-MDP类似物作为动物疫苗粘膜佐剂

• 批准号: 488280-2015
• 负责人: Jiang, ZiHua
• 金额: $ 1.82万
• 依托单位: Lakehead University
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=586169
• 关键词: Synthetic; lipo; MDP; analogs; mucosal

As the rise of bacterial resistance to antibiotics is becoming a worldwide problem, there is an urgent need for reducing antibiotic use in veterinary animals. The development of needle-free and cost-effective vaccines that trigger long-lasting immunity in large animals is challenging partly due to the lack of safe and potent adjuvants. Lilly Creek Vaccine (LCV) Inc. is developing new vaccine formulations that are particularly useful for mucosal vaccination. In partnership with LCV, we are going to study the potential of a group of structurally-defined adjuvants that are able to activate the immune system by interacting with a certain receptor molecule known as NOD2. After the chemical synthesis of these compounds, they will be evaluated for adjuvant activity in both in vitro and in vivo studies. The research is expected to provide new vaccine adjuvant candidates for further development. The proposed research will also facilitate the establishment of research collaboration between the applicant and LCV and generate new intellectual properties in developing veterinary health care products. The research outcome may eventually translate into significant economic and social benefits to Canada.

随着细菌对抗生素耐药性的上升正在成为一个世界性问题，迫切需要减少兽医动物中的抗生素使用。在大型动物中引发持久免疫力的无针和具有成本效益的疫苗的开发具有挑战性，部分原因是缺乏安全和有效的佐剂。Lilly Creek Vaccine（LCV）Inc.正在开发新的疫苗制剂，特别是用于粘膜接种。与LCV合作，我们将研究一组结构确定的佐剂的潜力，这些佐剂能够通过与某种称为NOD2的受体分子相互作用来激活免疫系统。在这些化合物的化学合成之后，将在体外和体内研究中评价它们的佐剂活性。该研究有望为进一步开发提供新的疫苗佐剂候选物。建议的研究亦会促进香港与 申请人和LCV，并在开发兽医保健产品方面产生新的知识产权。研究成果最终可能转化为加拿大的重大经济和社会效益。